The Effect of Mobile Health-based Exercise on Hepatocellular Carcinoma Patients With Insulin Resistance

Samsung Medical Center15 enrolled

Overview

Exercise is predicted to have positive effect among patients with hepatocellular carcinoma (HCC). However, little attention has been paid to the role of physical activity with wearable device in the management of HCC patients in the aspect of improvement in insulin resistance. We designed this study to investigate whether personalized exercise with mobile health program improves insulin resistance without decompensation in HCC patients with insulin resistance.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hepatocellular Carcinoma Insulin Resistance

Interventions

Mobile healthBEHAVIORAL

Perform exercise daily with mobile application and wearable device (warm-up, stretching, aerobic, and strengthening). Mobile application: Hepatocellular carcinoma by Second Doctor Wearable device: Dofit

Eligibility

Sex: ALLMin age: 20 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Patients aged 20 to 70 years * Patients who were diagnosed with early-stage HCC, defined by modified UICC stage 1 or 2 * Patients with treatment-naive and recurrent HCC who have received treatment and achieved complete response at the time of screening * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Patients with insulin resistance (HOMA-IR \>=2.2) Exclusion Criteria: * Child Pugh class B or C * Alcohol intake \>20g/day * History of decompensation * Severe medical comorbidities (ischemic heart disease, 3rd degree atrioventricular block, chronic obstructive pulmonary disease, severe hypertension (blood pressure \> 200/120 mmHg) or psychiatric illnesses which limit ability to exercise safely * Who takes insulin sensitizer (sulfonylurea, biguanide, thiazolidinedione, glucagon-like peptide-1 agonist, dipeptidyl peptidase-4 inhibitor) or uses insulin * Uncontrolled diabetes mellitus (Hemoglobin A1c \>10%)

Locations (1)

Moon Seok Choi

Seoul, South Korea

Outcomes

Primary Outcomes

Improvement of insulin resistance

The proportion of normalization of homeostatic model assessment of insulin resistance (HOMA-IR) (\<2.2)

Time frame: After 12 weeks

Secondary Outcomes

Improvement of insulin resistance

The proportion of normalization of homeostatic model assessment of insulin resistance (HOMA-IR) (\<2.2)

Time frame: After 24 weeks

Improvement of 6-minute walk test

\- Changes in meters assessed using the 6-minute walk test